Skip to main content
Premium Trial:

Request an Annual Quote

NaPro BioTherapeutics Establishes Genomics Division; University of Delaware s Kmiec Directs

NEW YORK, Sept. 18 — NaPro BioTherapeutics of Boulder, Col., said it recently established a genomics division, NaPro Genomics, under the scientific direction of Eric Kmiec at the University of Delaware’s Delaware Biotechnology Institute. Kmiec, who invented and developed a targeted gene repair technology that NaPro licensed, directs g enomics research at the institute and is an associate professor in the university’s department of biological sciences. NaPro develops and licenses genetic technologies for applications in therapeutics and diagnostics, pharmacogenomics, and agribiotechnology.

Several other researchers and clinicians in the areas of genetics,  genomics,  and genetic disease have also joined NaPro’s genomics scientific advisory board. Among them are: Robert Pollack, director of the Center for the Study of Science and Religion at Columbia University; John Weinstein, the soon-to-be head of the  Genomics  and  Bioinformatics  Group of the Laboratory of Molecular Pharmacology of the National Cancer Institute; and Nancy Wexler, Higgins professor of neuropsychology at the Columbia University College of Physicians and Surgeons and president of the Hereditary Disease Foundation. 

Commenting on his role as chairman of the scientific advisory board, Pollack said in a statement, “We have assembled a diverse group of articulate and productive scientists to help NaPro  Genomics  gain a full measure of clinical utility from our technologies. In particular, the expertise of the SAB will assist NaPro scientists in bringing this technology to bear on sickle-cell anemia, Huntington's disease, and the problem of the emergence of drug resistant cancer cells as a result of chemotherapy." 

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.